Self-lnactivating lentiviral vectors with U3 and U5 modifications

Virology

Volumn 261, Issue 1, 1999, Pages 120-132

  Iwakuma, Tomoo ^a   Cui, Yan ^a   Chang, Lung Ji ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR; HUMAN GROWTH HORMONE; IMMEDIATE EARLY PROTEIN; MESSENGER RNA; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENHANCER REGION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMEDIATE EARLY GENE; LENTIVIRINAE; LONG TERMINAL REPEAT; PLASMID; POLYADENYLATION; PRIORITY JOURNAL; PROMOTER REGION; RHABDOMYOSARCOMA; TATA BOX; VIRUS DNA CELL DNA INTERACTION; VIRUS INACTIVATION; ANIMAL; CATTLE; CELL CULTURE; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MUTAGENESIS; POLYMERASE CHAIN REACTION; PROVIRUS;

ANIMALS; CATTLE; CYTOMEGALOVIRUS; DNA, VIRAL; ENHANCER ELEMENTS (GENETICS); GENETIC VECTORS; HIV-1; HUMAN GROWTH HORMONE; HUMANS; IMMEDIATE-EARLY PROTEINS; LENTIVIRUS; MUTAGENESIS; PLASMIDS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROVIRUSES; RNA, MESSENGER; TERMINAL REPEAT SEQUENCES; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS INTEGRATION;

EID: 0033566372     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9850     Document Type: Article

References (40)

1. Adachi A., Gendelman H. E., Koenig S., Folks T., Willey R., Rabson A., Martin M. A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:1986;284-291.
2. Bishop J. M. Cellular oncogenes and retroviruses. Annu. Rev. Biochem. 52:1983;301-354.
3. Burns J. C., Friedmann T., Driever W., Burrascano M., Yee J. K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA. 90:1993;8033-8037.
4. Carroll R., Lin J. T., Dacquel E. J., Mosca J. D., Burke D. S., St. Louis D. C. A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines. J. Virol. 68:1994;6047-6051.
5. Chang L.-J., Urlacher V., Iwakuma T., Cui Y., Zucali J. Efficacy and safety analyses of a recombinant human immunodeficiency virus derived vector system. Gene Ther. 6:1999;715-728.
6. Chang L.-J., McNulty E., Martin M. Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. J. Virol. 67:1993;743-752.
7. Chang L.-J., Zhang C. Infection and replication of Tat-human immunodeficiency viruses: Genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells. Virology. 211:1995;157-169.
8. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:1987;2745-2752.
9. Cui Y., Iwakuma T., Chang L.-J. The contributions of viral splice sites and cis-regulatory elements on lentiviral vector functions. J. Virol. 73:1999;6171-6176.
10. Das A. T., Klaver B., Klasens B. I., van Wamel J. L., Berkhout B. A conserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication. J. Virol. 71:1997;2346-2356.
11. Gilmartin G. M., Fleming E. S., Oetjen J. Activation of HIV-1 pre-mRNA 3′ processing in vitro requires both an upstream element and TAR. EMBO J. 11:1992;4419-4428.
12. Gilmartin G. M., Fleming E. S., Oetjen J., Graveley B. R. CPSF recognition of an HIV-1 mRNA 3′-processing enhancer: Multiple sequence contacts involved in poly(A) site definition. Genes Dev. 9:1995;72-83.
13. Gordon E. M., Anderson W. F. Gene therapy using retroviral vectors. Curr. Opin. Biotechnol. 5:1994;611-616.
14. Huang Y., Khorchid A., Gabor J., Wang J., Li X., Darlix J. L., Wainberg M. A., Kleiman L. The role of nucleocapsid and U5 stem/A-rich loop sequences in tRNA(3Lys) genomic placement and initiation of reverse transcription in human immunodeficiency virus type 1. J. Virol. 72:1998;3907-3915.
15. Hunninghake G. W., Monick M. M., Liu B., Stinski M. F. The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. J. Virol. 63:1989;3026-3033.
16. Hwang J. J., Li L., Anderson W. F. A conditional self-inactivating retrovirus vector that uses a tetracycline-responsive expression system. J. Virol. 71:1997;7128-7131.
17. Kafri T., Blomer U., Peterson D. A., Gage F. H., Verma I. M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17:1997;314-317.
18. Kaul M., Yu H., Ron Y., Dougherty J. P. Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences. Virology. 249:1998;167-174.
19. Keller W. No end yet to messenger RNA 3′ processing. Cell. 81:1995;829-832.
20. Kim V. N., Mitrophanous K., Kingsman S. M., Kingsman A. J. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72:1998;811-816.
21. MacDonald C. C., Wilusz J., Shenk T. The 64-kilodalton subunit of the CstF polyadenylation factor binds to pre-mRNAs downstream of the cleavage site and influences cleavage site location. Mol. Cell. Biol. 14:1994;6647-6654.
22. Martin M., Noel D., Piechaczyk M. Towards efficient cell targeting by recombinant retroviruses. Mol. Med. Today. 3:1997;396-403.
23. Miller A. D., Miller D. G., Garcia J. V., Lynch C. M. Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 217:1993;581-599.
24. Miyoshi H., Blomer U., Takahashi M., Gage F. H., Verma I. M. Development of a self-inactivating lentivirus vector. J. Virol. 72:1998;8150-8157.
25. Miyoshi H., Takahashi M., Gage F. H., Verma I. M. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. USA. 94:1997;10319-10323.
26. Motmans K., Thirion S., Raus J., Vandevyver C. Isolation and quantification of episomal expression vectors in human T cells. Biotechniques. 23:1997;1044-1046.
27. Naldini L., Blomer U., Gage F. H., Trono D., Verma I. M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA. 93:1996a;11382-11388.
28. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F. H., Verma I. M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:1996b;263-267.
29. Olson P., Nelson S., Dornburg R. Improved self-inactivating retroviral vectors derived from spleen necrosis virus. J. Virol. 68:1994;7060-7066.
30. Poeschla E., Corbeau P., Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy. Proc. Natl. Acad. Sci. USA. 93:1996;11395-11399.
31. Poeschla E. M., Wong-Staal F., Looney D. J. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4:1998;354-357.
32. Reicin A. S., Kalpana G., Paik S., Marmon S., Goff S. Sequences in the human immunodeficiency virus type 1 U3 region required for in vivo and in vitro integration. J. Virol. 69:1995;5904-5907.
33. Robinson D., Elliott J. F., Chang L.-J. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat. Gene Ther. 2:1995;269-278.
34. Srinivasakumar N., Chazal N., Helga-Maria C., Prasad S., Hammarskjold M. L., Rekosh D. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J. Virol. 71:1997;5841-5848.
35. Temin H. M. Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum. Gene Ther. 1:1990;111-123.
36. Valsamakis A., Zeichner S., Carswell S., Alwine J. C. The human immunodeficiency virus type 1 polyadenylation signal: A 3′ long terminal repeat element upstream of the AAUAAA necessary for efficient polyadenylation. Proc. Natl. Acad. Sci. USA. 88:1991;2108-2112.
37. Verma I. M., Somia N. Gene therapy - Promises, problems and prospects. Nature. 389:1997;239-242.
38. Vicenzi E., Dimitrov D. S., Engelman A., Migone T. S., Purcell D. F., Leonard J., Englund G., Martin M. A. An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences. J. Virol. 68:1994;7879-7890.
39. Zufferey R., Dull T., Mandel R. J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:1998;9873-9880.
40. Zufferey R., Nagy D., Mandel R. J., Naldini L., Trono D. in vivo. Nat. Biotechnol. 15:1997;871-875.